CliffBio
small molecule

VONJO

PACRITINIB CITRATE

Loss of exclusivityMarch 2030latest FDA-listed patent expiry
CompanySOBI INC

Drug detail

Brand nameVONJO
Active ingredientPACRITINIB CITRATE
StrengthEQ 100MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusRX

Listed patents

PatentExpiresType
8980873March 2030substance, product
8153632January 2029substance, product
9573964May 2028use U-3331

Regulatory exclusivity

CodeExpires
ODE-397February 2029
NCEFebruary 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VONJO patent cliff — loss of exclusivity March 2030 | CliffBio